Response to: 'Glucosamine and mortality: a note of caution' by Conway

We appreciate the comments by Conway¹ on our manuscript which investigated the association of regular glucosamine use with all-cause and cause-specific mortality.²

First, we agree that the underlying mechanisms, including inhibition of nuclear factor- κ B thereby reducing inflammation and glucosamine triggering a mimic response of low carbohydrate diet, might partially explain the association between glucosamine use and mortality. Future studies are needed to better understand underlying pharmacological roles of glucosamine on health outcomes.

Second, the association of mortality with glucosamine use might be confused by unmeasured underlying lifestyle-related factors or other confounders. Nevertheless, in our analyses, we had carefully adjusted for several important confounders, including sociodemographic factors, lifestyle behaviours, health status, drug use and other supplements use. In total, 27 confounders were included in our fully adjusted models, and the adjustment for confounding was sufficient.

Third, randomised controlled trial (RCT) is indeed the ideal study design to clarify these issues. However, most previous RCTs, investigating the association between glucosamine use and health outcomes, mainly focused on the therapy in treating patients with osteoarthritis or other chronic diseases,^{3–5} who might have relatively poorer prognoses than healthy people in primary prevention trials. Moreover, several previous large-scale cohort studies found the similar magnitude of benefit of glucosamine on mortality,^{6–8} which are generally consistent with our study. Therefore, in the absence of sufficient sample size and sufficient trial duration, it might be difficult for previous RCTs to find such magnitude of benefit of glucosamine. Further studies are necessary to better clarify the association between glucosamine use and mortality.

Zhi-Hao Li, Qing-Mei Huang, Wen-Fang Zhong, Xi-Ru Zhang, Chen Mao

Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, Guangdong, China

Correspondence to Professor Chen Mao, Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, Guangdong 510515, China; maochen9@smu.edu.cn

Contributors Z-HL, Q-MH, W-FZ, X-RZ and CM wrote this manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Li Z-H, Huang Q-M, Zhong W-F, et al. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2020-218660

Received 21 July 2020

Accepted 25 July 2020

► <http://dx.doi.org/10.1136/annrheumdis-2020-218489>

Ann Rheum Dis 2020;**0**:1. doi:10.1136/annrheumdis-2020-218660

ORCID iD

Chen Mao <http://orcid.org/0000-0002-6537-6215>

REFERENCES

- 1 Conway. Glucosamine and mortality, a note of caution. *Ann Rheum Dis* 2020. 10.1136/annrheumdis-2020-218489
- 2 Li Z-H, Gao X, Chung VC, et al. Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study. *Ann Rheum Dis* 2020;79:829–36.
- 3 Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. *Cochrane Database Syst Rev* 2005;51:CD002946.
- 4 Towheed TE, Anastassiades TP. Glucosamine and chondroitin for treating symptoms of osteoarthritis: evidence is widely touted but incomplete. *JAMA* 2000;283:1483–4.
- 5 Runhaar J, Rozendaal RM, van Middelkoop M, et al. Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the oa trial bank. *Ann Rheum Dis* 2017;76:1862–9.
- 6 Bell GA, Kantor ED, Lampe JW, et al. Use of glucosamine and chondroitin in relation to mortality. *Eur J Epidemiol* 2012;27:593–603.
- 7 Ma H, Li X, Sun D, et al. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. *BMJ* 2019;365:l1628.
- 8 Pocobelli G, Kristal AR, Patterson RE, et al. Total mortality risk in relation to use of less-common dietary supplements. *Am J Clin Nutr* 2010;91:1791–800.